糖尿病網膜症市場：製品タイプ、糖尿病タイプ、患者タイプ、エンドユーザー別- 世界予測2025-2030年

糖尿病網膜症市場の2024年の市場規模は90億7,000万米ドルで、2025年にはCAGR 6.21％で96億2,000万米ドルに成長し、2030年には130億2,000万米ドルに達すると予測されています。

糖尿病網膜症は、依然として世界的に最も深刻な糖尿病合併症の一つであり、革新的なソリューションと市場促進要因の深い理解が求められる急速に進化する状況に影響を及ぼしています。最近の動向では、先進経済諸国と新興経済諸国の両方における糖尿病人口の増加が、高度な診断と治療介入に対する需要の増加に寄与しています。糖尿病有病率の上昇だけでなく、治療の可能性を広げた大幅な技術改善と研究のブレークスルーにより、市場は発展してきました。さらに、ヘルスケア専門家と患者の意識の高まりが、標的療法や最先端の外科的イノベーションを含む新しいアプローチへと業界を導いています。

このようなダイナミックな環境の中で、既存企業も新規参入企業も、最先端治療の可能性を活用するための研究開発に投資を行っています。本イントロダクションでは、包括的な市場洞察、業界動向、および利害関係者が複雑な糖尿病網膜症管理をナビゲートするのに役立つ戦略的フレームワークについて、より広範な議論の舞台を設定します。詳細な分析に入るにあたり、変革的な市場シフトの検証、様々な次元にわたる主要なセグメンテーション考察、競合戦略を再構築する地域動向の探求に焦点を当てる。最終的な目標は、臨床ニーズと市場機会をバランスさせ、治療イノベーションと治療戦略が持続可能な方法で患者の転帰を改善し続けることを確実にする、情報に基づいた意思決定への道を開くことです。

糖尿病網膜症市場の変革

糖尿病網膜症市場は、技術革新、患者中心の要求、規制当局の支援の相互作用によって、過去10年間に大きな変化を経験してきました。変化の大きな原動力となったのは、治療方法を再構築する新規医薬品と医療機器の登場です。画像診断や診断ツールの進歩は、臨床医に網膜の変化をより早い段階で発見する力を与え、病気の進行を抑えるタイムリーな介入を可能にしています。

デジタル・ヘルス・ソリューションや遠隔医療プラットフォームが従来のケアモデルを変革し始める中、技術統合も極めて重要な役割を果たしています。これらのソリューションは遠隔地からの診断と管理を容易にし、特に遠隔地や十分なサービスを受けていない地域における質の高いヘルスケアへのアクセスを拡大します。これと並行して、進化する償還政策と有利な政府の取り組みが、研究と市場拡大への投資をさらに後押ししています。

市場参入企業はこうした動向にいち早く対応し、患者一人ひとりのプロファイルに合わせた個別化治療レジメンへの傾向が強まっています。利害関係者は現在、データ分析と人工知能を活用して患者の転帰を予測し、治療プロトコルを最適化しています。このような適応は、単に臨床診療を再形成するだけでなく、市場参入と競争上の位置づけのための新たな道筋を築きつつあります。最終的に、こうした変革的なシフトは、糖尿病網膜症管理において、よりダイナミックで、迅速で、患者中心のエコシステムをもたらしています。

製品タイプ、糖尿病プロファイル、患者タイプ、エンドユーザー別の主なセグメンテーション洞察

市場セグメンテーションを徹底的に分析することで、糖尿病網膜症分野における様々な機会や課題を明らかにする複雑な構造が見えてくる。戦略的側面の1つは製品タイプに基づくもので、抗VEGF薬、副腎皮質ステロイド、レーザー機器、手術用インプラントなど複数の治療法について市場を精査しています。このうち、抗VEGF剤は、アフリベルセプト、ベバシズマブ、ラニビズマブなどの特定の薬剤を通してさらに評価され、重要な技術革新を推進し、堅調な市場成長を示しています。コルチコステロイド、特にデキサメタゾンやトリアムシノロンなどの変種は、既存のレジメンと統合することで患者の転帰を向上させる補完的な治療アプローチを提供します。

同様に重要なのは、非増殖糖尿病網膜症と増殖糖尿病網膜症を区別する、糖尿病タイプに基づく市場の区分です。このセグメンテーションにより、疾患の進行と、それに対応する最も効果的な治療プロトコルの微妙な理解が可能になります。もう1つの重要なセグメンテーションパラメータである患者タイプは、成人グループと小児グループを区別するもので、疾患の発現と治療反応がこれらの属性間で顕著に異なる可能性があることを認識しています。さらに、エンドユーザーに基づく分析には、外来手術センターからクリニックや病院まで、さまざまなヘルスケア施設が含まれます。これらの施設は、一般診療所や専門診療所などの構成要素にさらに細かく分類され、病院の場合はさらに私立と公立に分けられます。これらのセグメンテーションの洞察は戦略的なレンズとなり、利害関係者は特定の市場ニッチをターゲットとし、臨床的影響と商業的成功の両方を最大化するために提供物を最適化することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病管理と網膜ケアに対する政府の取り組みと資金提供が研究開発を促進
    • 糖尿病の罹患率の増加と眼疾患の早期発見に対する意識の高まりが市場の成長を促進
  • 抑制要因
    • 新興国では治療費が高く、ヘルスケアへのアクセスが限られているため、市場拡大が制限されている
  • 機会
    • 診断技術の進歩と患者の転帰を改善する新しい治療法の導入
    • 予防に関する患者教育を可能にするモバイルヘルスアプリケーションへの関心の高まり
  • 課題
    • 適切なスクリーニングプログラムの欠如と診断の遅れが不可逆的な視力喪失につながる
• 市場セグメンテーション分析
  • 製品タイプ：炎症を緩和し、黄斑浮腫を軽減するためのコルチコステロイドの需要の高まり
  • 糖尿病の種類：非増殖性糖尿病の増加
  • 患者タイプ：糖尿病の長期罹患により、成人における糖尿病網膜症の症例が増加している
  • エンドユーザー：糖尿病網膜症患者にアクセスしやすく専門的なケアを提供する外来手術センターの好感度が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 糖尿病網膜症市場：製品タイプ別

• 抗VEGF薬
  • アフリベルセプト
  • ベバシズマブ
  • ラニビズマブ
• コルチコステロイド
  • デキサメタゾン
  • トリアムシノロン
• レーザー機器
• 外科用インプラント

第7章 糖尿病網膜症市場糖尿病の種類別

• 非増殖性糖尿病網膜症
• 増殖性糖尿病網膜症

第8章 糖尿病網膜症市場患者タイプ別

• 成人用
• 小児科

第9章 糖尿病網膜症市場：エンドユーザー別

• 外来手術センター
• クリニック
  • 一般診療所
  • 専門クリニック
• 病院
  • 私立病院
  • 公立病院

第10章 南北アメリカの糖尿病網膜症市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の糖尿病網膜症市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの糖尿病網膜症市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• AEYE Health
• Amgen Inc.
• ANI Pharmaceuticals, Inc.
• Bausch+Lomb Corporation
• Bayer AG
• BCN Peptides, S.A.U.
• Boehringer Ingelheim International GmbH
• Clearside Biomedical, Inc.
• Eli Lilly and Company
• Eyenuk, Inc.
• EyePoint Pharmaceuticals, Inc.
• F. Hoffmann-La Roche AG
• Kodiak Sciences Inc.
• Novartis AG
• Ocugen, Inc.
• Ocular Therapeutix, Inc.
• Ocuphire Pharma, Inc.
• OcuTerra Therapeutics
• Opthea Limited
• Oxurion NV
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• REGENXBIO Inc.
• RetinaRisk
• RETMARKER
• Samsung Biologics Co., Ltd.

LIST OF FIGURES

• FIGURE 1. DIABETIC RETINOPATHY MARKET MULTI-CURRENCY
• FIGURE 2. DIABETIC RETINOPATHY MARKET MULTI-LANGUAGE
• FIGURE 3. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
• FIGURE 4. DIABETIC RETINOPATHY MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DIABETIC RETINOPATHY MARKET DYNAMICS
• TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 60. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 62. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 63. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 97. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 102. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 104. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 105. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 106. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 109. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 110. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 112. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 113. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 114. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 117. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 118. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 121. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 122. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 126. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 128. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 129. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 130. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 134. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 136. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 137. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 138. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 142. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 144. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 145. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 146. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 150. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 151. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 152. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 153. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 154. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 158. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 166. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 168. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 169. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 170. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 174. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 175. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 176. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 177. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 178. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 182. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 183. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 184. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 185. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 186. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 199. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 200. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 201. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 202. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 203. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 207. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 208. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 209. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 210. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 211. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 215. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 217. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 218. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 219. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 223. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 225. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 226. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 227. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 231. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 233. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 234. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 235. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 239. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 240. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 241. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 242. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 243. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 247. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 248. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 249. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 250. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 251. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 252. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 253. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 254. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 255. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 256. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 257. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 258. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 259. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 263. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 264. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 265. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 266. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 267. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 271. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 272. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 273. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 274. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 275. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 279. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 281. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 282. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 283. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 284. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 285. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 286. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 287. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 288. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 289. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 290. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 291. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 292. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 293. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 294. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 295. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 296. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 297. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 298. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 299. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 303. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 304. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 305. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 306. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 307. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 311. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 312. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 313. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 314. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 315. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 316. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 319. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 320. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 321. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 322. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 323. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 324. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 327. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 328. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 329. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 330. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 331. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 332. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 333. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 334. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 335. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 336. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 337. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 338. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
• TABLE 339. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 340. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 341. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
• TABLE 342. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 343. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 344. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
• TABLE 345. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
• TABLE 346. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)

TABLE 3

The Diabetic Retinopathy Market was valued at USD 9.07 billion in 2024 and is projected to grow to USD 9.62 billion in 2025, with a CAGR of 6.21%, reaching USD 13.02 billion by 2030.

Diabetic retinopathy remains one of the most critical complications of diabetes worldwide, influencing a rapidly evolving landscape that demands innovative solutions and a deep understanding of market drivers. In recent years, the rise in diabetic populations across both developed and emerging economies has contributed to an increased demand for advanced diagnostics and therapeutic interventions. The market has evolved not only due to the rising prevalence of diabetes but also because of significant technological improvements and research breakthroughs that have expanded treatment possibilities. Furthermore, heightened awareness among healthcare professionals and patients alike has steered the industry towards novel approaches, including targeted therapies and state-of-the-art surgical innovations.

In this dynamic environment, both incumbents and new entrants are channeling investments into research and development to harness the potential of cutting-edge treatments. This introduction sets the stage for a broader discussion on comprehensive market insights, industry trends, and strategic frameworks that can help stakeholders navigate the complexities of diabetic retinopathy management. As we delve into detailed analyses, the focus will be on examining transformative market shifts, dissecting key segmentation insights across various dimensions, and exploring regional trends that are reshaping competitive strategies. The ultimate goal is to pave the way for informed decision-making that balances clinical needs with market opportunities, ensuring that therapeutic innovations and treatment strategies continue to improve patient outcomes in a sustainable manner.

Transformative Shifts in the Diabetic Retinopathy Landscape

The diabetic retinopathy market has experienced profound transformations over the past decade, driven by an interplay of innovation, patient-centric demands, and regulatory support. A significant driver of change has been the advent of novel pharmaceuticals and medical devices that are reshaping treatment modalities. Advances in imaging and diagnostic tools have empowered clinicians to detect retinal changes at much earlier stages, enabling timely interventions that mitigate the progression of the disease.

Technological integration has also played a pivotal role as digital health solutions and telemedicine platforms begin to transform traditional care models. These solutions facilitate remote diagnosis and management, thereby expanding access to quality healthcare, especially in remote and underserved regions. In parallel, evolving reimbursement policies and favorable government initiatives have further encouraged investment in research and market expansion.

Market participants have been quick to adjust to these shifts, with an increasing trend towards personalized treatment regimens that are tailored to individual patient profiles. Stakeholders are now leveraging data analytics and artificial intelligence to predict patient outcomes and optimize treatment protocols. This adaptation is not just reshaping clinical practices but is also forging new pathways for market entry and competitive positioning. Ultimately, these transformative shifts are resulting in a more dynamic, responsive, and patient-centered ecosystem in diabetic retinopathy management.

Key Segmentation Insights Across Product, Diabetic Profile, Patient Type, and End-User

A thorough analysis of market segmentation reveals a complex structure that uncovers various layers of opportunity and challenge within the diabetic retinopathy sector. One strategic dimension is based on product type, where the market is scrutinized across multiple therapies including Anti-VEGF agents, corticosteroids, laser equipment, and surgical implants. Among these, Anti-VEGF agents, assessed further through specific drugs like Aflibercept, Bevacizumab, and Ranibizumab, have driven significant innovation and demonstrated robust market growth. Corticosteroids, particularly those variants including Dexamethasone and Triamcinolone, offer a complementary therapeutic approach that enhances patient outcomes when integrated with existing regimens.

Equally crucial is the dissection of the market based on diabetic type, which distinguishes between non-proliferative and proliferative diabetic retinopathy. This segmentation allows for a nuanced understanding of disease progression and the corresponding treatment protocols that are most effective. Patient type, another vital segmentation parameter, distinguishes between adult and pediatric groups, recognizing that disease manifestation and treatment responses can vary notably between these demographics. Additionally, analysis based on the end-user includes various healthcare facilities, ranging from ambulatory surgical centers to clinics and hospitals. These institutions are further detailed into components such as general and specialty clinics and, in the case of hospitals, further division into private and public establishments. Together, these segmentation insights provide a strategic lens, enabling stakeholders to target specific market niches and optimize their offerings to maximize both clinical impact and commercial success.

Based on Product Type, market is studied across Anti-VEGF Agents, Corticosteroids, Laser Equipment, and Surgical Implants. The Anti-VEGF Agents is further studied across Aflibercept, Bevacizumab, and Ranibizumab. The Corticosteroids is further studied across Dexamethasone and Triamcinolone.

Based on Diabetic Type, market is studied across Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy.

Based on Patient Type, market is studied across Adult and Pediatric.

Based on End-User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals.

Latest Regional Insights Shaping the Market Trends

Global market dynamics are influenced by regional trends that highlight diverse economic, regulatory, and clinical factors. In the Americas, strong regulatory frameworks combined with robust healthcare infrastructure have fueled a steady demand for advanced diabetic retinopathy treatments. This region is witnessing a significant uptake in novel therapeutic options, driven by continuous investments in healthcare technology and patient education initiatives.

In the combined region of Europe, Middle East & Africa, the market landscape is evolving rapidly with innovative treatments gaining ground amidst traditional therapy methods. Steady economic growth, coupled with aggressive government support initiatives, has fostered an environment ripe for innovation. Regulatory bodies in these regions are increasingly focusing on expediting approval processes for breakthrough drugs and devices, which in turn accelerates market adoption.

The Asia-Pacific region stands as one of the fastest-growing markets due to its large and diverse population. Emerging economies, rapid urbanization, and heightened health awareness have collectively contributed to increased investments in both research and sophisticated treatment methodologies. These regional trends underscore how local market conditions, regulatory environments, and healthcare infrastructure can significantly influence the pace at which diabetic retinopathy therapies are adopted. Overall, regional insights help delineate market potential and guide strategic initiatives tailored to specific geographic contexts.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Driving Innovation

The competitive landscape in diabetic retinopathy is marked by vigorous activity from both long-standing pharmaceutical giants and innovative startups. Industry leaders such as AbbVie Inc., Amgen Inc., and Bayer AG have been at the forefront of research and development, leveraging their extensive resources to pioneer novel treatment modalities. Companies like Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals, Inc. have successfully combined targeted therapies with robust clinical data, creating momentum that not only drives market growth but also sets the benchmark for future innovations.

Mid-sized companies and emerging players, including AEYE Health, ANI Pharmaceuticals, Inc., and Ocuphire Pharma, Inc., are contributing significantly to the competitive discourse by offering niche solutions that address specific patient needs. Other notable innovators such as Bayer AG, BCN Peptides, S.A.U., Clearside Biomedical, Inc., and Eyenuk, Inc. are developing technologies that enhance the precision of treatment delivery and improve overall patient outcomes. Furthermore, firms like EyePoint Pharmaceuticals, Inc. and Ocular Therapeutix, Inc. have been instrumental in broadening the therapy landscape through strategic alliances and breakthrough research initiatives. With a diverse mix of established entities and fresh entrants, companies including Ocugen, Inc., OcuTerra Therapeutics, Opthea Limited, Oxurion NV, REGENXBIO Inc., RetinaRisk, RETMARKER, and Samsung Biologics Co., Ltd. are collectively shaping an ecosystem that thrives on innovation and collaborative ventures. These insights help outline a competitive roadmap that is both dynamic and forward-thinking, encouraging stakeholders to align their strategies with evolving clinical and market imperatives.

The report delves into recent significant developments in the Diabetic Retinopathy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AEYE Health, Amgen Inc., ANI Pharmaceuticals, Inc., Bausch + Lomb Corporation, Bayer AG, BCN Peptides, S.A.U., Boehringer Ingelheim International GmbH, Clearside Biomedical, Inc., Eli Lilly and Company, Eyenuk, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Novartis AG, Ocugen, Inc., Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., OcuTerra Therapeutics, Opthea Limited, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., REGENXBIO Inc., RetinaRisk, RETMARKER, and Samsung Biologics Co., Ltd.. Actionable Recommendations for Industry Leaders to Capitalize on Opportunities

Industry leaders looking to secure a competitive edge in the diabetic retinopathy market should consider a multi-pronged approach to strategize effectively. First, it is crucial to invest in research and development partnerships that facilitate the integration of advanced technologies such as AI-driven diagnostics and personalized therapy regimens. This will not only accelerate the transition from traditional treatment models but also pave the way for more precise and patient-tailored interventions.

Investors and market players should also consider leveraging data analytics to glean deep insights into patient demographics and treatment efficacy. Such an approach enables companies to optimize resource allocation and develop targeted strategies that directly address unmet clinical needs. Additionally, it is beneficial to build strong collaborations with health authorities and regulatory bodies to ensure a seamless pathway for product approvals and market penetration. Ultimately, a well-orchestrated strategy that integrates technological innovation with robust market intelligence will be critical in navigating the intricacies of this complex market landscape.

Conclusion: Strategic Perspectives for Future Growth

In conclusion, the diabetic retinopathy market is positioned for significant development owing to technological advancements and evolving treatment paradigms. The interplay of innovative therapies, tailored segmentation strategies, and targeted regional expansion has created a rich tapestry of opportunities for industry players. By harnessing data insights and embracing collaborative innovation, stakeholders can unlock new avenues for growth and establish a robust presence in this dynamic market. This executive summary provides a solid foundation for understanding the current landscape and sets the stage for strategic decisions aimed at improving patient outcomes and driving long-term value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Government initiatives and funding for diabetes management and retinal care boosting research and development
    • 5.1.1.2. Increasing prevalence of diabetes and rising awareness about early eye disease detection fueling market growth
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of treatment and limited access to healthcare in emerging economies restricting market expansion
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in diagnostic technologies and introduction of novel therapies enhancing patient outcomes
    • 5.1.3.2. Growing interest in mobile health applications enabling patient education on diabetic retinopathy prevention
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of adequate screening programs and late diagnosis leading to irreversible vision loss
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Growing need for corticosteroids to alleviate inflammation and reduce macular edema
  • 5.2.2. Diabetic Type: Increasing prevelance of non-proliferative diabetic retinopathy
  • 5.2.3. Patient Type: Growing instances of diabetic retinopathy in adults ages due to the prolonged duration of diabetes
  • 5.2.4. End-User: Rising preference for ambulatory surgical centers to provide accessible and specialized care for diabetic retinopathy patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Diabetic Retinopathy Market, by Product Type

• 6.1. Introduction
• 6.2. Anti-VEGF Agents
  • 6.2.1. Aflibercept
  • 6.2.2. Bevacizumab
  • 6.2.3. Ranibizumab
• 6.3. Corticosteroids
  • 6.3.1. Dexamethasone
  • 6.3.2. Triamcinolone
• 6.4. Laser Equipment
• 6.5. Surgical Implants

7. Diabetic Retinopathy Market, by Diabetic Type

• 7.1. Introduction
• 7.2. Non-Proliferative Diabetic Retinopathy
• 7.3. Proliferative Diabetic Retinopathy

8. Diabetic Retinopathy Market, by Patient Type

• 8.1. Introduction
• 8.2. Adult
• 8.3. Pediatric

9. Diabetic Retinopathy Market, by End-User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Clinics
  • 9.3.1. General Clinics
  • 9.3.2. Specialty Clinics
• 9.4. Hospitals
  • 9.4.1. Private Hospitals
  • 9.4.2. Public Hospitals

10. Americas Diabetic Retinopathy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Diabetic Retinopathy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Diabetic Retinopathy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Retina Consultants of America to be acquired by Cencora for up to USD 5.1 billion
  • 13.3.2. Eyenuk and AAO partner to bring diabetic retinopathy screening to underserved communities
  • 13.3.3. Google partners with Indian and Thai healthcare businesses to combat diabetic retinopathy using AI technology
  • 13.3.4. Innovative partnership leverages advanced AI technology to enhance diabetic retinopathy screening efforts
  • 13.3.5. Merck acquires EyeBio for USD 3 billion
  • 13.3.6. DocGo and Spect partner to reduce care gaps and improve eye and vision health
  • 13.3.7. ANI Pharmaceuticals to acquire Alimera Sciences
  • 13.3.8. FDA's approval of AEYE Health's autonomous AI transforms diabetic retinopathy screening using portable devices
  • 13.3.9. Exonate's groundbreaking EXN407 eye drop shows promise in treating diabetic retinopathy and macular oedema
  • 13.3.10. PolyPhotonix receives NPIF backing for diabetic retinopathy mask
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. Novartis AG
  • 13.4.2. Eli Lilly and Company
  • 13.4.3. Bayer AG
  • 13.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. AEYE Health
• 3. Amgen Inc.
• 4. ANI Pharmaceuticals, Inc.
• 5. Bausch + Lomb Corporation
• 6. Bayer AG
• 7. BCN Peptides, S.A.U.
• 8. Boehringer Ingelheim International GmbH
• 9. Clearside Biomedical, Inc.
• 10. Eli Lilly and Company
• 11. Eyenuk, Inc.
• 12. EyePoint Pharmaceuticals, Inc.
• 13. F. Hoffmann-La Roche AG
• 14. Kodiak Sciences Inc.
• 15. Novartis AG
• 16. Ocugen, Inc.
• 17. Ocular Therapeutix, Inc.
• 18. Ocuphire Pharma, Inc.
• 19. OcuTerra Therapeutics
• 20. Opthea Limited
• 21. Oxurion NV
• 22. Pfizer, Inc.
• 23. Regeneron Pharmaceuticals, Inc.
• 24. REGENXBIO Inc.
• 25. RetinaRisk
• 26. RETMARKER
• 27. Samsung Biologics Co., Ltd.